HK1076401A1 - Liquid pharmaceutical formulations of palonosetron - Google Patents

Liquid pharmaceutical formulations of palonosetron

Info

Publication number
HK1076401A1
HK1076401A1 HK05111168A HK05111168A HK1076401A1 HK 1076401 A1 HK1076401 A1 HK 1076401A1 HK 05111168 A HK05111168 A HK 05111168A HK 05111168 A HK05111168 A HK 05111168A HK 1076401 A1 HK1076401 A1 HK 1076401A1
Authority
HK
Hong Kong
Prior art keywords
palonosetron
pharmaceutical formulations
liquid pharmaceutical
emesis
concentration
Prior art date
Application number
HK05111168A
Other languages
English (en)
Inventor
Calderari Giorgio
Bonadeo Daniele
Cannella Roberta
Braglia Enrico
Branglia Riccardo
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32825409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1076401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of HK1076401A1 publication Critical patent/HK1076401A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
    • B65B55/02—Sterilising, e.g. of complete packages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK05111168A 2003-01-30 2005-12-07 Liquid pharmaceutical formulations of palonosetron HK1076401A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44435103P 2003-01-30 2003-01-30
PCT/EP2004/000888 WO2004067005A1 (en) 2003-01-30 2004-01-30 Liquid pharmaceutical formulations of palonosetron

Publications (1)

Publication Number Publication Date
HK1076401A1 true HK1076401A1 (en) 2006-01-20

Family

ID=32825409

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111168A HK1076401A1 (en) 2003-01-30 2005-12-07 Liquid pharmaceutical formulations of palonosetron

Country Status (41)

Country Link
US (9) US7947724B2 (no)
EP (2) EP1601359B1 (no)
JP (2) JP5461763B2 (no)
KR (1) KR101113084B1 (no)
CN (2) CN102813621A (no)
AP (1) AP2110A (no)
AR (1) AR042977A1 (no)
AT (1) ATE410167T1 (no)
AU (1) AU2004208505C1 (no)
BR (1) BRPI0407121B8 (no)
CA (5) CA2573194A1 (no)
CR (1) CR7921A (no)
CY (1) CY1108660T1 (no)
DE (1) DE602004016967D1 (no)
DK (1) DK1601359T3 (no)
EA (1) EA014066B1 (no)
EC (1) ECSP055938A (no)
ES (1) ES2315635T3 (no)
GE (1) GEP20084445B (no)
HK (1) HK1076401A1 (no)
HR (1) HRP20050676B1 (no)
IL (1) IL169859A (no)
IS (1) IS7984A (no)
JO (1) JO2735B1 (no)
MA (1) MA27710A1 (no)
MX (1) MXPA05008028A (no)
MY (1) MY144036A (no)
NO (1) NO329500B1 (no)
NZ (1) NZ541533A (no)
PA (1) PA8594801A1 (no)
PE (1) PE20050066A1 (no)
PL (1) PL378398A1 (no)
PT (1) PT1601359E (no)
RS (1) RS20050578A (no)
SI (1) SI1601359T1 (no)
TN (1) TNSN05180A1 (no)
TW (1) TWI342212B (no)
UA (1) UA90449C2 (no)
UY (1) UY28175A1 (no)
WO (1) WO2004067005A1 (no)
ZA (1) ZA200506917B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
CN100455286C (zh) * 2006-11-21 2009-01-28 深圳海创医药科技发展有限公司 帕洛诺司琼注射液及其制备方法
WO2008153725A2 (en) 2007-05-25 2008-12-18 North Carolina State University Viral nanoparticle cell-targeted delivery platform
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
EP2364138A2 (en) 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
JP2013510843A (ja) 2009-11-13 2013-03-28 ヘルシン ヘルスケア ソシエテ アノニム パロノセトロン代謝産物先行出願との関連本出願は２００９年１１月１３日に出願された米国仮出願第６１／２６０，９１６号の優先権を主張する。
ES2494015T3 (es) 2009-11-18 2014-09-12 Helsinn Healthcare Sa Composiciones para tratar nauseas y vómitos de origen central
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
DK2744497T3 (en) 2011-10-18 2016-08-01 Helsinn Healthcare Sa THERAPEUTIC COMBINATION OF netupitant AND palonosetron
US9877959B2 (en) 2013-12-23 2018-01-30 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
CN104784107A (zh) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 一种盐酸托烷司琼口服液的制备方法
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
PL3435980T3 (pl) * 2016-06-06 2020-05-18 Helsinn Healthcare Sa Fizjologicznie zrównoważone preparaty fosnetupitantu do wstrzykiwania
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
PL3737378T3 (pl) * 2018-01-12 2023-07-31 Orion Corporation Krople do oczu z palonosetronem do leczenia nudności i wymiotów lub zapobiegania im
JP7090845B2 (ja) * 2018-08-03 2022-06-27 高田製薬株式会社 パロノセトロン含有液体組成物
JP7438802B2 (ja) * 2020-03-23 2024-02-27 シオノギファーマ株式会社 パロノセトロン含有組成物
TW202428273A (zh) * 2023-01-03 2024-07-16 瑞士商赫爾辛保健公司 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS599539B2 (ja) * 1979-11-13 1984-03-03 日本化薬株式会社 ニトログリセリン水溶液及びその製造法
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
EP0498466B1 (en) 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
FI98367C (fi) * 1989-11-28 1997-06-10 Syntex Inc Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi
DK0583421T3 (da) 1991-05-03 1999-11-22 Searle & Co Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP3845902B2 (ja) * 1996-07-09 2006-11-15 ソニー株式会社 磁気記録再生装置
ATA156496A (de) 1996-09-03 1997-10-15 Nycomed Austria Gmbh Pharmazeutische zusammensetzung
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
DE19833119A1 (de) 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6284749B1 (en) * 1998-10-27 2001-09-04 Alcon Manufacturing, Ltd. Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
KR20030070073A (ko) * 2000-12-20 2003-08-27 브리스톨-마이어스스퀴브컴파니 세로토닌 효능제 및 길항제로서의 치환된 피리도인돌
US7211596B2 (en) 2001-05-11 2007-05-01 Mitsubishi Pharma Corporation Stable high-concentration injection containing pyrazolone derivative
AU2003237657A1 (en) 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
CA2505990C (en) 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
AU2003303210A1 (en) * 2002-12-19 2004-07-14 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
EP1567163B1 (en) 2003-01-13 2007-04-11 Dynogen Pharmaceuticals Inc. Method of treating nausea, vomiting, retching or any combination thereof
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting

Also Published As

Publication number Publication date
NO329500B1 (no) 2010-11-01
BRPI0407121A (pt) 2006-01-10
US20140097114A1 (en) 2014-04-10
MA27710A1 (fr) 2006-01-02
CY1108660T1 (el) 2014-04-09
CN102813621A (zh) 2012-12-12
AU2004208505B2 (en) 2009-09-03
EP1601359B1 (en) 2008-10-08
TW200418517A (en) 2004-10-01
US20110192493A1 (en) 2011-08-11
JP5461763B2 (ja) 2014-04-02
CR7921A (es) 2006-02-07
CA2573241A1 (en) 2004-08-12
PE20050066A1 (es) 2005-04-20
JP2006516583A (ja) 2006-07-06
HRP20050676A2 (en) 2005-10-31
US20130267553A1 (en) 2013-10-10
MXPA05008028A (es) 2006-01-27
PT1601359E (pt) 2008-11-03
US7960424B2 (en) 2011-06-14
AU2004208505C1 (en) 2015-10-01
ZA200506917B (en) 2006-08-30
JP5551658B2 (ja) 2014-07-16
BRPI0407121B1 (pt) 2018-07-17
JO2735B1 (en) 2013-09-15
CA2573228A1 (en) 2004-08-12
EA200501203A1 (ru) 2006-06-30
TWI342212B (en) 2011-05-21
NO20053987L (no) 2005-08-26
EP1601359A1 (en) 2005-12-07
JP2011236242A (ja) 2011-11-24
US7947725B2 (en) 2011-05-24
ATE410167T1 (de) 2008-10-15
US20160000773A1 (en) 2016-01-07
PA8594801A1 (es) 2004-09-16
AU2004208505A2 (en) 2004-08-12
AU2004208505A1 (en) 2004-08-12
ES2315635T3 (es) 2009-04-01
RS20050578A (en) 2007-09-21
IL169859A (en) 2014-11-30
US20160317440A1 (en) 2016-11-03
US7947724B2 (en) 2011-05-24
CA2514224C (en) 2009-11-03
CA2573194A1 (en) 2004-08-12
US20060167071A1 (en) 2006-07-27
US9308266B2 (en) 2016-04-12
TNSN05180A1 (en) 2007-06-11
US8598218B2 (en) 2013-12-03
KR20050104363A (ko) 2005-11-02
CN1758911A (zh) 2006-04-12
EA014066B1 (ru) 2010-08-30
US20060069114A1 (en) 2006-03-30
US9457020B2 (en) 2016-10-04
WO2004067005A1 (en) 2004-08-12
US20140039000A1 (en) 2014-02-06
AP2005003382A0 (en) 2005-09-30
EP2008659A1 (en) 2008-12-31
DE602004016967D1 (de) 2008-11-20
PL378398A1 (pl) 2006-04-03
UY28175A1 (es) 2004-09-30
CA2573363A1 (en) 2004-08-12
AR042977A1 (es) 2005-07-13
IS7984A (is) 2005-08-15
UA90449C2 (ru) 2010-05-11
MY144036A (en) 2011-07-29
BRPI0407121B8 (pt) 2021-06-29
CA2514224A1 (en) 2004-08-12
GEP20084445B (en) 2008-08-10
KR101113084B1 (ko) 2012-02-15
ECSP055938A (es) 2006-03-01
SI1601359T1 (sl) 2009-04-30
DK1601359T3 (da) 2009-01-05
NZ541533A (en) 2008-12-24
US20060167073A1 (en) 2006-07-27
US8518981B2 (en) 2013-08-27
HRP20050676B1 (hr) 2013-02-28
AP2110A (en) 2010-03-01

Similar Documents

Publication Publication Date Title
HK1076401A1 (en) Liquid pharmaceutical formulations of palonosetron
PE20050438A1 (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
JP2005289996A5 (no)
JP2005343897A5 (no)
MY153718A (en) Formulation of human antibodies for treating tnf-(?) associated disorders
ATE269056T1 (de) Hochwirksame dihydroergotaminhaltige arzneizusammensetzungen
CY1115766T1 (el) Καθαρισμος και σταθεροποιηση πεπτιδιου και πρωτεϊνων σε φαρμακευτικους παραγοντες
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
PT1311285E (pt) Composicao farmaceutica liquida contendo um derivado de eritropoietina
CY1109146T1 (el) Υγρο φαρμακευτικο σκευασμα που περιλαμβανει νικοτινη για τη χορηγηση στην στοματικη κοιλοτητα
LT2001119A (en) Pharmaceutical formulations comprising intranasal morphine and use thereof
PT1256339E (pt) Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
ATE505183T1 (de) Den geschmack verdeckende auslaufsichere formulierung
WO2008070721A3 (en) High protein concentration formulations containing mannitol
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
DE60206871D1 (de) Pharmazeutische Formulierung enhaltend Midazolam zur buccalen Verabreichung
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate
MXPA04004907A (es) Composiciones de acetaminofen.
ATE352287T1 (de) Flüssige pharmazeutische zusammensetzungen auf wasserbasis in suspensionsform zur oralen verabreichung von ibuprofen
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
SE0203817D0 (sv) New composition
UY24297A1 (es) Nuevo procedimiento para la formulación de fármacos
TH145992A (th) สูตรของสารภูมิต้านทานในมนุษย์สำหรับการบำบัดความผิดปกติที่เกี่ยวเนื่องกับ thf-(อัลฟา)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130130